Thanks to our supporters, a new observational study aimed at identifying markers that predict how Coronavirus (COVID-19) affects patients is being led by clinicians and academics at North Bristol NHS Trust and the University of Bristol.
The DISCOVER (DIagnostic and Severity markers of COVID-19 to Enable Rapid triage) study is focused on blood-based biomarkers and their ability to predict a patient’s disease course alongside demographic factors such as age, sex, frailty and other medical conditions.
When patients with suspected or confirmed Covid-19 are admitted to hospital, they will be approached by the research team and consented for blood sampling and access to their medical history.
These patients will then be followed up for 28 days, remotely, and their clinical progress recorded. Blood samples from the study will be stored anonymously for future research.
One biomarker the research team will test is suPAR (soluble urokinase plasminogen activating receptor), which has already had encouraging results from Greek data, alongside other more conventional tests, such as troponin, NT-proBNP and ferritin. The team will also test a variety of molecules that control the immune system, known as “cytokines”.
The importance of this research can’t be overstated. Although the majority of patients with COvid-19 recover quickly, doctors do not yet know the best way to predict which patients to keep in hospital to monitor more closely. This early triage of patients is crucial to manage the pressure on hospital beds safely.
“We hope to rapidly publish this work and share our results with other UK and international centres to allow wider use of successful prognostic biomarkers. Our study could help doctors in the future decide which tests are useful in managing coronavirus and which are not.”Dr David Arnold, Respiratory Registrar at Southmead Hospital and NIHR Doctoral Research Fellow at Bristol Medical School
Patients admitted to University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) will shortly join the North Bristol NHS Trust led study, with hospitals in Exeter and Gloucester entering in the coming weeks.
“One of the key strengths of DISCOVER is that despite the rapid speed of application, ethical approval, and data collection, plans were made early to collaborate with both local and national researchers to ensure that any samples or data collected will be available to ensure the benefit to the wider research community, and ultimately, to patients. We have developed many collaborations over a short period, including with the UNCOVER group and Public Health England.”Dr Fergus Hamilton, Honorary Research Fellow in the Bristol Medical School
We are honoured to be able to support such a vital project, and it is thanks to all our donors and supporters that we are able to fund such life-saving work. This ground-breaking research project has also received funding from the University’s Elizabeth Blackwell Institute.